相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
Leo Kretzner et al.
CANCER RESEARCH (2011)
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Mark Kirschbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells
Chie Nishioka et al.
LEUKEMIA RESEARCH (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Chromatin Remodeling Is Required for Gene Reactivation after Decitabine-Mediated DNA Hypomethylation
Jiali Si et al.
CANCER RESEARCH (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
Warren Fiskus et al.
CANCER BIOLOGY & THERAPY (2009)
Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
Ken Shiozawa et al.
CLINICAL CANCER RESEARCH (2009)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Andres O. Soriano et al.
BLOOD (2007)
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
William Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia-Manero et al.
BLOOD (2006)
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
Blanca Sanchez-Gonzalez et al.
BLOOD (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
SD Gore et al.
CANCER RESEARCH (2006)
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome
P Maslak et al.
LEUKEMIA (2006)
Epigenetic therapy of cancer: past, present and future
CB Yoo et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
An epigenetic approach to the treatment of advanced MDS;: the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
PW Wijermans et al.
ANNALS OF HEMATOLOGY (2005)
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
P Reddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxarmic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
R Nimmanapalli et al.
BLOOD (2003)
Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
RW Johnstone
NATURE REVIEWS DRUG DISCOVERY (2002)